Jones D, Hayes M, Webb S, French C, Bellomo R
Department of Intensive Care, Royal Perth Hospital, Western Australia.
Anaesth Intensive Care. 2006 Oct;34(5):599-605. doi: 10.1177/0310057X0603400506.
A recent study reported that 77% of patients with septic shock had relative adrenal insufficiency. However, all patients were mechanically ventilated and received high-dose inotropes. In addition, at least 24% had prior exposure to etomidate, a drug known to suppress adrenal function. We studied the incidence of relative adrenal insufficiency in etomidate-naïve patients with septic shock by analysing the adrenal response to high-dose short synacthen test in 113 consecutive patients from three university-affiliated intensive care units in Australia. Patients were allocated to three groups according to severity of illness and inclusion criteria of the trial of low dose hydrocortisone supplementation using information from patient records. Of the 113 patients, 98 had septic shock (Group A). The incidence of relative adrenal insufficiency in this subpopulation was 24.5%. Eighty-one per cent of patients with septic shock were mechanically ventilated (Group B). In this group, the incidence of relative adrenal insufficiency was 27.8%. Only 38 of the 98 patients with septic shock (39%) fulfilled inclusion criteria for the steroid supplementation trial (Group C). In this group, the incidence of relative adrenal insufficiency was only 34.2%. In all groups its presence was associated with a higher mortality. We conclude that the incidence of relative adrenal insufficiency in etomidate-naive septic shock patients was lower than observed in the steroid supplementation trial. Further, in those who fulfilled inclusion criteria for the trial, the incidence of relative adrenal insufficiency was half that reported by the trial. Our observations raise concerns about the generalizability of the findings of the above trial to etomidate-naïve patients.
最近一项研究报告称,77%的感染性休克患者存在相对肾上腺皮质功能不全。然而,所有患者均接受机械通气并使用了大剂量的血管活性药物。此外,至少24%的患者曾使用过依托咪酯,这是一种已知会抑制肾上腺功能的药物。我们通过分析澳大利亚三家大学附属医院重症监护病房连续113例患者对大剂量短程促肾上腺皮质激素试验的肾上腺反应,研究了未使用依托咪酯的感染性休克患者中相对肾上腺皮质功能不全的发生率。根据病情严重程度和低剂量氢化可的松补充试验的纳入标准,利用患者记录中的信息将患者分为三组。113例患者中,98例患有感染性休克(A组)。该亚组中相对肾上腺皮质功能不全的发生率为24.5%。感染性休克患者中有81%接受机械通气(B组)。该组中相对肾上腺皮质功能不全的发生率为27.8%。98例感染性休克患者中只有38例(39%)符合类固醇补充试验的纳入标准(C组)。该组中相对肾上腺皮质功能不全的发生率仅为34.2%。在所有组中,其存在均与较高的死亡率相关。我们得出结论,未使用依托咪酯的感染性休克患者中相对肾上腺皮质功能不全的发生率低于类固醇补充试验中的观察结果。此外,在符合试验纳入标准的患者中,相对肾上腺皮质功能不全的发生率是该试验报告的一半。我们的观察结果引发了对上述试验结果能否推广至未使用依托咪酯患者的担忧。